Ignite Creation Date:
2024-05-05 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00481520
Status:
COMPLETED
Last Update Posted:
2009-09-30
First Post:
2007-05-30
Brief Title:
Study Evaluating the SafetyTolerability PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimers Disease
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Safety Tolerability Pharmacokinetics PK Pharmacodynamics PD Trial of Multiple Ascending Fixed Doses of SAM-531 in Subjects With Mild to Moderate Alzheimers Disease
Status:
COMPLETED
Status Verified Date:
2008-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of the study is to assess whether SAM-531 an investigational drug is safe and well tolerated compared with placebo a medically inactive substance in subjects with mild to moderate Alzheimers disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None